The U.S. Food and Drug Administration has approved Sklice to treat head lice for nonprescription, or over-the-counter (OTC) use. The FDA initially approved Sklice (ivermectin) lotion, 0.5% for the treatment of head lice infestation in patients 6 months of age and older as a prescription drug in February 2012.

A new study investigating a community-based pediculicidal ointment, Tinospora crispa, has revealed that T. crispa pediculicidal ointment is safe, effective and has acceptable physicochemical characteristics.

A study conducted in two neighbouring villages of Sine-Saloum, Senagal, analysed the effect of using oral Ivermectin and shampoo in the treatment of pediculosis and revealed that whilst oral ivermectin is more highly effective in treating pediculosis compared with shampoo, ivermectin resitance may emerge during treatment.

A study undertaken to determine the ovicidal efficacy of abametapir against eggs of both human head and body lice has revealed that abametaphir has an 100% ovicidal activity in vitro assessments and therefore able to inhibit hatching of both head and body louse eggs if used in specific concetrations.

The head lice brand Hedrin has announced the launch of a Stubborn Egg Loosening Lotion and suggested that this new addition to the Hedrin family would make it easy to remove dead eggs from the hair after treatment.

New commentary warns of the risks of excessive use of ivermectin for unauthorized groups.

A new treated coat-stand is being trialled in France, aiming to reduce the spread of head-lice in schools.

A summary of recent pediculosis product news.

Tyratech have recently announced a deal to sell Vamousse, their preventative head lice treatment product, through Walmart in the US.

The anti-lice product DeOvo, developed by Hatchtech Pty Ltd, has successfully completed its end-of-phase II consultations with the FDA.